VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer

Study Purpose

a. VEGFRs may be the biomarker which can predict the effect of bevacizumab in non small cell lung cancer

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational [Patient Registry]
Eligible Ages 18 Years - 75 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

- non squamous cell non small cell lung cancer - with measurable disease - ECOG 0-1

Exclusion Criteria:

- patients received surgery in recent 4 weeks

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT01891708
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Li Liu
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Li Liu, MD
Principal Investigator Affiliation Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Recruiting
Countries China
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Non Small Cell Lung Cancer, Brain Metastasis
Additional Details

1. non small cell lung cancer (non squamous carcinoma) 2. ECOG 0-1 3. from 18-75 years old

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Wuhan, Hubei, China

Status

Recruiting

Address

Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430071

Site Contact

Li Liu, MD

liulixiehe@163.com

027-85872015

Stay Informed & Connected